Almotriptan for the treatment of acute migraine: a review of early intervention trials

References

• World Health Organization. The Global Burden of Disease: 2004 Update. WHO, Geneva, Switzerland (2004).
   Google Scholar
• International Headache Society. The International Classification of Headache Disorders (Second Edition). Blackwell Publishing, Oxford, UK (2005).
   Google Scholar
• Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch. Neurol.59(7), 1084–1088 (2002).
   PubMed Web of Science ®Google Scholar
• Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur. J. Neurol.12(Suppl. 1), 1–27 (2005).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Saxena PR, Dahlöf C et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain123(Pt 1), 9–18 (2000).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet358(9294), 1668–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia22(8), 633–658 (2002). Erratum in: Cephalalgia23, 71 (2003).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Block G, Dahlöf C et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia20(9), 765–786 (2000).
   PubMed Web of Science ®Google Scholar
• Gendolla A. Early treatment in migraine: how strong is the current evidence? Cephalalgia28(Suppl. 2), 28–35 (2008).
   PubMedGoogle Scholar
• Freitag FG, Finlayson G, Rapoport AM et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS). Headache47(4), 519–530 (2007).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Zanchin G, Geraud G et al. Early vs. non-early intervention in acute migraine – ‘Act when Mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia28(4), 383–391 (2008).
   PubMed Web of Science ®Google Scholar
• Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache43(1), 36–43 (2003).
   PubMed Web of Science ®Google Scholar
• Edmeads J. Understanding the needs of migraine patients. Drugs66(Suppl. 3), 1–8 (2006).
   Web of Science ®Google Scholar
• Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann. Neurol.47(5), 614–624 (2000).
   PubMed Web of Science ®Google Scholar
• Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol.55(1), 19–26 (2004).
   PubMed Web of Science ®Google Scholar
• Pryse-Phillips W, Aubé M, Bailey P et al. A clinical study of migraine evolution. Headache46(10), 1480–1486 (2006).
   PubMed Web of Science ®Google Scholar
• Gras J. Almotriptan, a new anti-migraine agent: a review. CNS Drug Rev.8, 217–234 (2002).
   PubMedGoogle Scholar
• Láinez MJ. Almotriptan: meeting today’s needs in acute migraine treatment. Expert Rev. Neurother.7(12), 1659–1673 (2007).
   PubMedGoogle Scholar
• Dahlöf CG, Pascual J, Dodick DW, Dowson AJ. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia26(4), 400–408 (2006).
   PubMed Web of Science ®Google Scholar
• Mathew NT. Almotriptan increases pain-free status in patients with acute migraine treated in placebo-controlled clinical trials. Headache42(Suppl. 1), 32–37 (2002).
   Web of Science ®Google Scholar
• Cady R. Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis. Headache42(Suppl. 1), 26–31 (2002).
   PubMedGoogle Scholar
• Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache41(5), 449–455 (2001).
   PubMed Web of Science ®Google Scholar
• Mathew NT; for the Oral Almotriptan Study Group. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine. Headache42(1), 32–40 (2002).
   Web of Science ®Google Scholar
• Pascual J, Falk R, Docekal R et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur. Neurol.45(4), 206–213 (2001).
   PubMed Web of Science ®Google Scholar
• World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J. Postgrad. Med.48(3), 206–208 (2002).
   PubMed Web of Science ®Google Scholar
• Antonaci F, Chimento P, Diener HC, Sances G, Bono G. Lessons from placebo effects in migraine treatment. J. Headache Pain8(1), 63–66 (2007).
   PubMedGoogle Scholar
• Solomon S. A review of mechanisms of response to pain therapy: why voodoo works. Headache42(7), 656–662 (2002).
   PubMedGoogle Scholar
• Dodick DW. Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials. Headache42(1), 21–27 (2002).
   PubMed Web of Science ®Google Scholar
• Dodick DW, Sandrini G, Williams P. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs21(1), 73–82 (2007).
   PubMed Web of Science ®Google Scholar
• Láinez MJ, Galván J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur. J. Neurol.14(3), 269–275 (2007).
   PubMed Web of Science ®Google Scholar
• Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache42(1), 28–31 (2002).
   PubMed Web of Science ®Google Scholar
• Mathew NT. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache43(10), 1075–1079 (2003).
   PubMed Web of Science ®Google Scholar
• Sandrini G, Dahlöf CG, Mathew N, Nappi G. Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine. Int. J. Clin. Pract.59(11), 1356–1365 (2005).
   PubMedGoogle Scholar
• Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan improves response rates when treatment is within | 1 hour of migraine onset. Headache44(4), 318–322 (2004).
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Massiou H, Laínez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia22(6), 453–461 (2002).
   PubMed Web of Science ®Google Scholar
• Pascual J, Láinez JM, Leira R et al. [Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study]. Neurologia18(1), 7–17 (2003).
   PubMed Web of Science ®Google Scholar
• Pascual J, Tranche S, Leira R, Lainez JM, Mateos V, Galvan J. Almotriptan in clinical practice: experience in a primary care vs neurology setting. Headache43, 525 (2003).
   Google Scholar
• Láinez MJ, Pascual J, Mateos V, Galvan J. Real world experience comparing neurologists and primary care physician management of acute migraine with almotriptan in Spain. Presented at: 56th Annual Meeting of the American Academy of Neurology. San Francisco, CA, USA, 24 April–1 May 2004.
   Google Scholar
• Mathew NT, Finlayson G, Smith TR et al. Early intervention with almotriptan: results of the AEGIS trial (AXERT® Early Migraine Intervention Study). Headache47(2), 189–198 (2007).
   PubMed Web of Science ®Google Scholar
• Freitag F, Smith T, Mathew N et al. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. Headache48(3), 341–354 (2008).
   PubMed Web of Science ®Google Scholar
• Lantéri-Minet M, Allaf B, Mick G. Right triptan use in clinical conditions: results of TEMPO study. Neurology66(5 Suppl. 2), A43 (2006).
   Google Scholar
• Díaz-Insa S, Goadsby PJ, Zanchin G et al. Early treatment with almotriptan allows a good outcome even in allodynic migraine patients. An Act when Mild (AwM) substudy. Presented at: European Headache and Migraine Trust International Congress. London, UK, 4–7 September 2008 (Poster PC 02).
   Google Scholar
• Schoenen J, De Klippel N, Giurgea S et al. Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. Cephalalgia28(10), 1095–1105 (2008).
   PubMed Web of Science ®Google Scholar
• Cady R, Martin V, Mauskop A et al. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. Cephalalgia27(9), 1055–1060 (2007).
   PubMed Web of Science ®Google Scholar
• Janknegt R, Steenhoek A. The System of Objectified Judgement Analysis (SOJA). A tool in rational drug selection for formulary inclusion. Drugs53(4), 550–562 (1997).
   PubMed Web of Science ®Google Scholar
• Janknegt R. Triptans in the treatment of migraine: drug selection by means of the SOJA method. Expert Opin. Pharmacother.8(Suppl. 1), S15–S30 (2007).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Dodick DW, Ferrari MD, McCrory DC, Williams P. TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. Acta Neurol. Scand.110(3), 137–143 (2004).
   PubMed Web of Science ®Google Scholar
• Kaniecki R. Headache assessment and management. JAMA289(11), 1430–1433 (2003).
   PubMedGoogle Scholar
• Dodick DW. Applying the benefits of the AwM study in the clinic. Cephalalgia28(Suppl. 2), 42–49 (2008).
   PubMed Web of Science ®Google Scholar
• De Klippel N, Jansen JP, Carlos JS. Survey to evaluate diagnosis and management of headache in primary care: Headache Management Pattern programme. Curr. Med. Res. Opin.24(12), 3413–3422 (2008).
   PubMedGoogle Scholar
• Foley KA, Cady R, Martin V et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache45(5), 538–545 (2005).
   PubMed Web of Science ®Google Scholar
• Ng-Mak DS, Cady R, Chen YT, Ma L, Bell CF, Hu XH. Can migraineurs accurately identify their headaches as “migraine” at attack onset? Headache47(5), 645–653 (2007).
   PubMed Web of Science ®Google Scholar
• Kelman L, Von Seggern RL. Using patient-centered endpoints to determine the cost–effectiveness of triptans for acute migraine therapy. Am. J. Ther.13(5), 411–417 (2006).
   PubMedGoogle Scholar
• Williams P, Reeder CE. A comparison of the cost–effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. J. Manag. Care Pharm.10(3), 259–265 (2004).
   PubMedGoogle Scholar
• Gori S, Morelli N, Acuto G, Caiola F, Iudice A, Murri L. A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy. Minerva Med.97(6), 467–477 (2006).
   PubMedGoogle Scholar
• Freitag F. Pharmacoeconomic benefits of almotriptan in the acute treatment of migraine. Expert Rev. Pharmacoecenomics Outcomes Res.8(2), 105–110 (2008).
   PubMedGoogle Scholar
• Slof J, Láinez J, Comas A, Heras J. Almotriptan vs. ergotamine plus caffeine for acute migraine treatment. A cost–efficacy analysis. Neurologia24, 147–153 (2009).
   PubMedGoogle Scholar